NCT04081688: Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC |
|
|
| Active, not recruiting | 1 | 16 | US | Atezolizumab 1200 MG in 20 ML Injection, ATEZOLIZUMAB, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy, Varlilumab 3 mg/kg, CDX 1127, CDX-1127, Immunoglobulin G1, Anti-(Human CD Antigen CD27) (Human Monoclonal CDX-1127 Clone 1f5 Heavy Chain), Disulfide with Human Monoclonal CDX-1127 Clone 1f5 Kappa-chain, Dimer, VARLILUMAB | Rutgers, The State University of New Jersey, National Cancer Institute (NCI) | Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | 04/22 | 04/24 | | |
NCT02924038: A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) |
|
|
| Terminated | 1 | 14 | US | IMA950, IMA950 peptides, poly-ICLC, Hiltonol, Varlilumab, CDX-1127 | Nicholas Butowski, Celldex Therapeutics, National Cancer Institute (NCI) | Glioma, Malignant Glioma, Astrocytoma, Grade II, Oligodendroglioma, Glioma, Astrocytic, Oligoastrocytoma, Mixed | 12/22 | 12/22 | | |
